化疗联合调强放射治疗局部进展期非小细胞肺癌患者的疗效分析  

Efficacy of chemotherapy combined with IMRT in the treatment of patients with locally advanced non-small cell lung cancer

作　　者：徐升[1] 张军宁[1] 甘广辉 XU Sheng;ZHANG Jun-ning;GAN Guang-hui(Department of Radiotherapy,The First Affiliated Hospital of Soochow University,Soochow 215006,Jiangsu,China)

机构地区：[1]苏州大学附属第一医院放疗科,苏州医学硕士215006

出　　处：《医学研究生学报》2018年第8期835-839,共5页Journal of Medical Postgraduates

基　　金：苏州市科技计划项目(SYS201462)

摘　　要：目的目前临床治疗中利用调强放射治疗(IMRT)联合化疗治疗非小细胞癌(NSCLC)的研究较少。文中旨在分析化疗联合IMRT治疗局部进展期NSCLC患者的疗效及对生存质量的影响。方法选择2012年1月至2014年12月苏州大学附属第一医院放疗科收治的160例局部进展期NSCLC患者,根据治疗方式不同分为IMRT组(紫杉醇或吉西他滨联合顺铂化疗,调强放射治疗)和对照组(仅紫杉醇或吉西他滨联合顺铂化疗),每组80例。比较2组患者治疗效果及对患者生存质量的影响。结果 IMRT组治疗有效率高于对照组(78.75%vs 47.50%,P<0.05)。IMRT组患者1年、2年、3年生存率(70.00%、52.50%、36.25%)明显高于对照组(52.50%、36.25%、21.25%),差异有统计学意义(P<0.05)。IMRT组患者中位疾病进展时间、中位生存期明显大于对照组[8.9 vs 6.3个月,14.2 vs 11.1个月],差异均有统计学意义(P<0.05)。IMRT组不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论局部进展期NSCLC者采用化疗联合IMRT能显著提高治疗效果,不良反应较少,安全性高,明显延长患者生存期,值得临床推广使用。Objective At present,there are few studies on the application of intensity-modulated radiation therapy(IMRT)combined with chemotherapy in the treatment of non-small cell carcinoma(NSCLC).The article aimed to analyze the efficacy of chemotherapy combined with IMRT on patients with locally advanced NSCLC and the impact on life quality. Methods From January 2012 to December 2014,160 patients with locally advanced NSCLC were treated in our department of radiotherapy.The patients were divided into IMRT group(chemotherapy of paclitaxel or gemcitabine combined with cisplatin,IMRT)and control group(chemotherapy of paclitaxel or gemcitabine combined with cisplatin)according to different treatments,80 patients in each group.The patients′treatment efficacy along with its impact on the patients′life quality were compared between two groups. Results The effective rate of IMRT group was higher than that of control group(78.75%vs 47.50%,P<0.05).The 1-year,2-year,3-year survival rates were 70.00%,52.50%,36.25%in IMRT group and 52.50%,36.25%and 21.25%in control group,and the differences were of statistical significance(P<0.05).The median duration of the disease and the median survival time in IMRT group were significantly longer than those in control group(8.9 months vs 6.3 months,14.2 months vs 11.1 months,P<0.05).No significant difference was found as to the incidence of toxic and side effects between two groups(P>0.05). Conclusion Chemotherapy combined with IMRT can significantly improve the therapeutic effect in patients with locally advanced NSCLC,featuring less side effects,high safety,improved life quality and lengthened survival time.Therefore,the treatment is worthy of clinical application.

关 键 词：化疗 调强放射治疗 联合治疗 局部进展期非小细胞肺癌 生存分析 

分 类 号：R734.2[医药卫生—肿瘤]